Investment
Features
FeesSafety
Academy
More
Pluang+

IBM to announce Q3 2026 earnings in webcast on Oct 21, 2026

Company Fundamentals
07 Oct 2026
PRNewsWire
View Source
Neutral
IBM to announce Q3 2026 earnings in webcast on Oct 21, 2026

IBM will hold a live webcast on October 21, 2026, at 5:00 p.m. ET to discuss its financial results for the third quarter of 2026. Investors can access the webcast and related materials on IBM's investor website. The event will include prepared remarks and charts, with a replay available after the call. This quarterly update provides insight into IBM's recent performance and outlook.

IBM's upcoming third-quarter 2026 financial results announcement is the subject. For readers following Technology-sector US stocks, here is Pluang's market snapshot as of Oct 07, 2026 20:01 WIB: Of 150 priced stocks, 33 rose and 112 fell. Notable movers include LRCX at USD 323.30 with a -3.17% change and Pluang order activity of 39% Sell / 61% Buy, APLD at USD 24.57 with a -3.04% change and 16% Sell / 84% Buy, and ASX at USD 45.40 with a -2.95% change and 23% Sell / 77% Buy.

More News

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

Hormel Foods price target cut to $23 amid hopes for valuation rebound despite 50% share drop.

BNP Paribas lowered Hormel Foods' price target from $26 to $23, indicating a potential 16.2% upside from its current price of around $19.80. Despite a 50.5% decline in its share price over five years, Hormel Foods remains attractive for dividend inve...

Analyst Insights
Neutral
58 minutes ago
Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays rates Becton Dickinson 'Underweight' amid $3B U.S. manufacturing partnership

Barclays initiated coverage of Becton, Dickinson and Company (BDX) with an "Underweight" rating, indicating a cautious outlook for the medical technology stock. BDX is partnering with the U.S. government to boost domestic manufacturing and strengthen...

Market News
Bearish
1 hour ago
Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley raises Eli Lilly price target to $1,430, signaling 20.8% potential upside.

Morgan Stanley increased its price target for Eli Lilly to $1,430 from $1,419, maintaining an Overweight rating. This new target implies a potential upside of about 20.8% from the current share price of around $1,184. The adjustment reflects updated ...

Analyst Insights
Bullish
1 hour ago
Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher sees 6% organic growth; analysts split on price targets amid mixed outlook.

Arthur J. Gallagher expects about 6% organic growth in Q3, driven by strong client retention and new business despite easing property insurance pricing. Cantor Fitzgerald lowered its price target to $280, below the $288 average from 19 analysts who m...

Analyst Insights
Bullish
2 hours ago
Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Zscaler's price target raised to $255 on strong AI-driven cybersecurity demand and growth outlook.

Needham raised Zscaler's price target to $255, citing strong demand for AI-related cybersecurity solutions. Zscaler aims to exceed $8 billion in annual recurring revenue by fiscal 2031, driven by increasing needs to protect against AI-powered cyberat...

Analyst Insights
Bullish
3 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App